Hugh M Cole Insider Trading $JNCE Jounce Therapeutics, Inc.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Hugh M Cole.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Hugh M Cole. Hugh M Cole is SVP, Chief Business Officer in ARIAD PHARMACEUTICALS INC ($ARIA) and Director in CATABASIS PHARMACEUTICALS INC ($CATB) and Chief Business Officer in Jounce Therapeutics, Inc. ($JNCE).
Hugh M Cole in Jounce Therapeutics, Inc.
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Hugh M Cole: Chief Business Officer
Holdings: 73,889 shares
Current Value: $1,278,280
Latest Transaction: Feb 03 2021
$JNCE Market Capitalization: $140.99M
$JNCE Previous Close: $17.30
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Hugh M Cole in Jounce Therapeutics, Inc.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ARIA, CATB, JNCE
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 03 2021 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Option Exercise | A | 11.89 | 53,400 | 634,926 | 53,400 | |
| Feb 03 2021 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Grant | A | 0.00 | 26,700 | 0 | 73,889 | 47.2 K to 73.9 K (+56.58 %) |
| Jan 25 2021 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Option Exercise | M | 6.55 | 5,000 | 32,750 | 55,000 | |
| Jan 25 2021 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Option Exercise | M | 4.40 | 5,000 | 22,000 | 39,500 | |
| Jan 25 2021 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 11.95 | 18,000 | 215,100 | 47,189 | 65.2 K to 47.2 K (-27.61 %) |
| Jan 25 2021 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Buy | M | 6.55 | 5,000 | 32,750 | 65,189 | 60.2 K to 65.2 K (+8.31 %) |
| Jan 25 2021 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Buy | M | 4.40 | 5,000 | 22,000 | 60,189 | 55.2 K to 60.2 K (+9.06 %) |
| Jan 11 2021 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 7.00 | 3,340 | 23,380 | 55,189 | 58.5 K to 55.2 K (-5.71 %) |
| Jan 11 2021 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 6.76 | 2,879 | 19,462 | 58,529 | 61.4 K to 58.5 K (-4.69 %) |
| Aug 18 2020 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 4.71 | 744 | 3,504 | 61,408 | 62.2 K to 61.4 K (-1.20 %) |
| Aug 18 2020 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 4.86 | 454 | 2,206 | 62,152 | 62.6 K to 62.2 K (-0.73 %) |
| Aug 18 2020 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 4.64 | 984 | 4,566 | 62,606 | 63.6 K to 62.6 K (-1.55 %) |
| Feb 04 2020 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Option Exercise | A | 6.55 | 60,000 | 393,000 | 60,000 | |
| Feb 04 2020 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Grant | A | 0.00 | 30,000 | 0 | 63,590 | 33.6 K to 63.6 K (+89.31 %) |
| Jan 10 2020 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 7.78 | 2,624 | 20,415 | 33,590 | 36.2 K to 33.6 K (-7.25 %) |
| Jan 10 2020 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 7.78 | 2,624 | 20,415 | 33,590 | 36.2 K to 33.6 K (-7.25 %) |
| Aug 16 2019 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 3.92 | 1,018 | 3,991 | 36,214 | 37.2 K to 36.2 K (-2.73 %) |
| Aug 16 2019 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 4.00 | 648 | 2,592 | 37,232 | 37.9 K to 37.2 K (-1.71 %) |
| Aug 16 2019 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Sell | S | 4.10 | 670 | 2,747 | 37,880 | 38.6 K to 37.9 K (-1.74 %) |
| Feb 05 2019 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Option Exercise | A | 4.40 | 44,500 | 195,800 | 44,500 | |
| Feb 05 2019 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Grant | A | 0.00 | 22,250 | 0 | 38,550 | 16.3 K to 38.6 K (+136.50 %) |
| Aug 15 2018 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Grant | A | 0.00 | 14,400 | 0 | 16,300 | 1.9 K to 16.3 K (+757.89 %) |
| Jun 18 2018 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Buy | P | 7.84 | 1,900 | 14,896 | 1,900 | 0 to 1.9 K |
| Feb 05 2018 | JNCE | Jounce Therapeutic ... | Cole Hugh M | Chief Business Offi ... | Option Exercise | A | 23.98 | 70,500 | 1,690,590 | 70,500 |
Page: 1